<DOC>
	<DOCNO>NCT02670122</DOCNO>
	<brief_summary>This observational , multicenter , single arm , prospective study evaluate safety tolerability selective ultraselective drug elute bead transcatheter intraarterial chemoembolization ( DEB-TACE ) 3 ml well calibrate 100 µ microspheres 150 mg doxorubicin , treatment non resectable hepatocellular carcinoma ( HCC ) . The hypothesis 100 µ bead penetrate deep tumor elute bead large volume without increase risk complication DEB-TACE .</brief_summary>
	<brief_title>Prospective Study Evaluate Safety Deb-TACE With 100µ Beads Patients With Non Resectable HCC</brief_title>
	<detailed_description>In observational , prospective study patient undergo DEB-TACE subsequent follow procedure accord standard clinical practice . The primary aim study describe treatment safety tolerability 100 µ bead DEB-TACE . As secondary end-point description efficacy parameter obtain .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>1 . Patients diagnosis HCC accord European Association Study Liver ( EASL ) American Association Study Liver Diseases ( AASLD ) criterion stag BCLC criterion 2 . Indication receive transarterial chemoembolization DEBTACE 100 µ microspheres accord usual clinical practice . 3 . Able willing participate give write informed consent . 4 . Both gender ≥ 18 year old . 5 . Eastern Cooperative Oncology Group ( ECOG ) 0 6 . Preserved hepatic function ( ChildPugh ≤ B7 ) . 7 . No evidence tumoral invasion portal vein main biliary duct . 8 . Able go image diagnostic technique CT MRI . 9 . Preserved cardiac renal function . 10 . No concomitant active infection require antibiotic treatment . 11 . Measurable disease accord mRECIST criterion . 12 . Life expectancy 6 month . 1 . ECOG ≥ 1 2 . ChildPugh ≥B8 . 3 . Presence ascitis encephalopathy 4 . Extrahepatic tumoral disease . 5 . Tumoral vascular invasion 6 . Serum bilirubin &gt; 3 mg/dl . 7 . Cr Clearance ≤ 60 ml/min 8 . If follow contraindicate : 1 . Administration doxorubicin 2 . Iodated contrast 3 . CT MRI procedures 4 . Transarterial embolization procedure 5 . White blood cell ( WBC ) &lt; 2000 /mm3 6 . Neutrophil count &lt; 1500 /mm3 7 . Ejection fraction &lt; 50 % 8 . Platelet count &lt; 5 x 104/mm3 , international normalize ratio ( INR ) &gt; 2,0 ) 9 . Transaminases ( AST and/or ALT ) &gt; 5x upper limit normal &gt; 250 u/l 10 . Known hepatofugal portal vein flow 11 . AV intrahepatic macroscopic fistula 9 . Pregnant breast feed woman . 10 . Tumor burden involve 50 % liver . 11 . Active bacterial fungal infection . 12 . Other concomitant tumor . 13 . Any condition accord investigator criterion , contraindicate DEBTACE . 14 . Patients willing participate and/or give write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>TACE</keyword>
</DOC>